Compare Norwegian Cruise Line Holdings Ltd (NCLH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Norwegian Cruise Line Holdings Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Norwegian Cruise Line Holdings Ltd trades at $15.57 (market cap $7.11B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 3.3× Recursion Pharmaceuticals Inc's market cap, and Recursion Pharmaceuticals Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Norwegian Cruise Line Holdings Ltd for 68 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| NCLH | RXRX | |
|---|---|---|
Market Cap | $7.11B | $2.14B |
Volume | 22,683,268 | 30,789,535 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.02 | $6.79 |
52-Week Low | $14.12 | $2.84 |
Typical Hold Time | 68 Days | 23 Days |
Enterprise Value | $21.93B | $1.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Norwegian Cruise Line Holdings (NCLH) trades at $15.49, up 2.92% on the day, with a bullish technical signal and recent earnings beats driving momentum. The company shows strong profitability with a 7.49% net income margin and attractive valuation metrics, including a P/E of 9.39. Recent news highlights management's focus on booking strategies and debt management, with a $950 million senior notes offering priced in September 2026. Analyst consensus is positive, with a $20.86 price target implying significant upside from current levels.
The outlook for NCLH is cautiously optimistic, supported by earnings strength and analyst buy ratings, but risks include high debt levels and yield pressure. Investment opportunity lies in valuation discount and operational improvements, though investors must monitor competitive dynamics and macroeconomic sensitivity. The stock's trajectory hinges on sustained demand and effective capital allocation.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
